Corporate VCs Step Up Carefully to Fill VC Void
Executive SummaryAs institutional venture firms gird themselves for difficult times ahead in raising new funds, investment programs at pharmaceutical companies and large medical device companies are at least partially filling the gap by committing corporate dollars into private life sciences companies, even in earlier stages.
You may also be interested in...
Promethera's Cell Therapy Attracts Corporate VCs To Largest European Biopharma Funding Round This Year
Belgium's Promethera raises $31.4 million to start clinical trials of its cell therapy for orphan liver diseases in a Series B funding